Search Results - "Sangalang, Emma R."

Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication by Theruvath, Johanna, Menard, Marie, Smith, Benjamin A. H., Linde, Miles H., Coles, Garry L., Dalton, Guillermo Nicolas, Wu, Wei, Kiru, Louise, Delaidelli, Alberto, Sotillo, Elena, Silberstein, John L., Geraghty, Anna C., Banuelos, Allison, Radosevich, Molly Thomas, Dhingra, Shaurya, Heitzeneder, Sabine, Tousley, Aidan, Lattin, John, Xu, Peng, Huang, Jing, Nasholm, Nicole, He, Andy, Kuo, Tracy C., Sangalang, Emma R. B., Pons, Jaume, Barkal, Amira, Brewer, Rachel E., Marjon, Kristopher D., Vilches-Moure, Jose G., Marshall, Payton L., Fernandes, Ricardo, Monje, Michelle, Cochran, Jennifer R., Sorensen, Poul H., Daldrup-Link, Heike E., Weissman, Irving L., Sage, Julien, Majeti, Ravindra, Bertozzi, Carolyn R., Weiss, William A., Mackall, Crystal L., Majzner, Robbie G.

“…The disialoganglioside GD2 is overexpressed on several solid tumors, and monoclonal antibodies targeting GD2 have substantially improved outcomes for children…”
Get full text

1121 TAC-003, a TLR9 agonist antibody conjugate for targeted immunotherapy of Nectin-4 expressing tumors by Chen, Amy, Li, Min, Sangalang, Emma RB, Fontaine, Danielle, Chou, Tiffany, An, Mingrui, Bonacorsi, Maja, Han, Bora, Wan, Hong I, Costa, Maria Jose, Strop, Pavel

“…BackgroundActivation of Toll-Like Receptor 9 (TLR9) by unmethylated CpG oligodeoxynucleotides (CpG ODNs) promotes innate and adaptive immune responses. Tumor…”
Get full text

Abstract 1721: TAC-001, a toll-like receptor 9 (TLR9) agonist antibody conjugate targeting B cells, promotes anti-tumor immunity and favorable safety profile following systemic administration in preclinical models by Kuo, Tracy C., Harrabi, Ons, Chen, Amy, Sangalang, Emma R., Doyle, Laura, Fontaine, Danielle, Li, Min, Han, Bora, Pons, Jaume, Sim, Janet, Wan, Hong I.

“…Abstract Novel therapies capable of engaging both innate and adaptive immune responses may engender durable anti-tumor immunity. Activation of toll-like…”
Get full text

Abstract 562: Antibodies to Sirpα enhance innate and adaptive immune responses to promote anti-tumor activity by Kuo, Tracy C., Chen, Amy, Harrabi, Ons, Kauder, Steven E., Sangalang, Emma R., Doyle, Laura, Bollini, Sangeetha, Han, Bora, Sim, Janet, Pons, Jaume, Wan, Hong I.

“…Abstract Targeting the CD47-SIRPα myeloid checkpoint pathway represents a novel therapeutic approach to enhance anti-cancer immunity. CD47 is a widely…”
Get full text

Abstract 6746: A B-cell targeted TLR9 agonist antibody conjugate potentiates cancer vaccine efficacy and rejuvenates vaccine responses in the elderly by Bonacorsi, Maja Z., Chen, Amy, Harrabi, Ons, Li, Min, Sangalang, Emma R., Fontaine, Danielle, Sim, Janet, Strop, Pavel, Wan, Hong I., Costa, Maria Jose

“…Abstract TLR9 agonists (unmethylated CpG oligodeoxynucleotides) are clinically validated as vaccine adjuvants and cancer therapeutics1,2. We developed a…”
Get full text